Feb 12, 2020 by Greg JonesAbbVie Is a Dividend Growth Stock at a Bargain PriceAbbVie reported fourth-quarter results that topped expectations. Its valuation discount is no longer warranted.
Feb 8, 2020 by Greg JonesGilead Sciences: Still on the Path to RecoveryGilead released a mixed fourth-quarter earnings report. Longer-term investors should stick with the stock.
Feb 7, 2020 by Greg JonesCoca-Cola's Earnings: Outperforming Its PeersCoca-Cola reported better-than-expected fourth quarter earnings. This is likely to be more the rule than the exception going forward.
Feb 5, 2020 by Greg JonesAltria's Earnings: Bull Case Still Intact for This Dividend Growth StockAltria's shares fell on disappointing earnings. However, a closer look suggests that the stock remains attractive for long-term investors.
Jan 30, 2020 by Greg JonesWells Fargo: Not Ready to Throw in the TowelThe news seems to go from bad to worse for Wells Fargo. But with a new CEO on board, could we be on the verge of a new dawn for the stock?
Jan 29, 2020 by Greg JonesIBM: Is Big Blue Set for Sustained Growth?IBM released earnings that were better than expected. Although the results were mixed, investors should be taking a closer look at the stock.
Dec 26, 2019 by Greg JonesWhy Cisco Systems is Overdue for a ReboundMacroeconomic factors have clouded Cisco's recent performance. With those clouds now parting, the stock deserves a second look.
Dec 19, 2019 by Greg JonesBottom-Fishing The Energy Sector With ChevronThe energy sector seems overdue for a rebound. Chevron may be the best way to play it.
Dec 14, 2019 by Greg JonesIs Warren Buffett's Berkshire Hathaway Still a Good Bet?Berkshire has lagged the market over the recent past. It's time for the shares to play catch up.
Dec 11, 2019 by Greg JonesWhat Would Warren Buffett's Mentor Think About Accenture?On many dimensions, Accenture qualifies as a great company. But is it a great investment?
Dec 7, 2019 by Greg JonesBristol Myers Squibb: A Cash-Generating Machine at a Cheap PriceThis big pharma stock provides value in an increasingly expensive market.
Nov 27, 2019 by Greg JonesWhy AbbVie Is a Dividend Growth Stock That's Too Cheap to IgnoreThe Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.
Nov 24, 2019 by Greg JonesIs IBM Ready for a Big Surge?IBM is lagging behind its technology peers. But its acquisition of Red Hat earlier this year may be a game changer.
Nov 19, 2019 by Greg JonesWells Fargo: Time to Climb Aboard the StagecoachWith a new CEO on board, Wells Fargo can start to put its problems behind it.
Nov 13, 2019 by Greg JonesIs Altria Going Up in Smoke or Just Going Up?Persistent bad news has driven the tobacco company to its lowest valuation in 10 years. It’s time to have a second look.
Nov 8, 2019 by Greg JonesIs The Future Finally Looking Up For Gilead Sciences?It’s been a rough ride for Gilead Sciences. But the biotech may soon be sailing through smoother seas.
